<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00945126</url>
  </required_header>
  <id_info>
    <org_study_id>ZKI-SCT-HAPLO-0106</org_study_id>
    <nct_id>NCT00945126</nct_id>
  </id_info>
  <brief_title>Allogeneic Stem Cell Transplantation in Pediatric Patients With Malignant and Non-malignant High-risk Diseases</brief_title>
  <official_title>Allogeneic Stem Cell Transplantation With CD3/CD19 Depleted Stem Cells of Related or Unrelated Haploidentical Donors in Pediatric Patients With Malignant and Non-malignant Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate the feasibility and toxicity of allogeneic
      haploidentical or unrelated transplantation with CD3/CD19 depleted stem cells associated with
      a reduced or a standard conditioning regimen in pediatric patients with malignant and
      non-malignant high-risk diseases, for whom allogeneic stem cell transplantation represents
      the only possible therapy option and no human leukocyte antigen (HLA) compatible related
      donors are available.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate engraftment after CD3/CD19 depletion of the graft</measure>
    <time_frame>within 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate immunoreconstitution after transplantation by assessing lymphocyte subsets</measure>
    <time_frame>within 1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">68</enrollment>
  <condition>Malignant and Non-malignant High Risk Diseases</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hematopoietic stem cell product from haploidentical or unrelated donor CD3/CD19 depleted with CliniMACS</intervention_name>
    <description>The aim is to transplant 7x106 CD34+/kg of recipient body weight.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 0 to 30 years

          -  Written informed consent from patient and/or parents or guardian

          -  Patients with Karnofsky Index &gt; 60%

          -  Malignant disease:

               -  acute lymphoblastic leukemia

               -  acute myeloid leukemia

               -  myelodysplastic syndrome

               -  chronic myeloid leukemia according to the standard indications

               -  solid tumors (e.g. neuroblastoma recurrence, soft-tissue sarcoma, Ewing's
                  sarcoma, osteosarcoma, hepatoblastoma)

                  . Non malignant disease:

               -  acquired anemias (e.g. severe aplastic anemia, particularly severe Evans
                  syndrome)

               -  congenital anemias (e.g. thalassemia and sickle cell anemia)

          -  Women reliable contraception method when appropriate

        Exclusion Criteria:

          -  Participation in other clinical trials

          -  Patients, parents, or guardians unable to understand the nature, the importance and
             the implications of the procedure

          -  Pregnant or nursing women

          -  Patients who underwent a stem cell transplantation in the last 250 days

          -  Patients with kidney, heart or liver insufficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Bader, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Frankfurt, Dept. for Children and Adolescents, Division for Stem Cell Transplantation, Goethe University.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Frankfurt, Dept. for Children and Adolescents, Division for Stem Cell Transplantation, Goethe University</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2009</study_first_submitted>
  <study_first_submitted_qc>July 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2009</study_first_posted>
  <last_update_submitted>September 28, 2017</last_update_submitted>
  <last_update_submitted_qc>September 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospital</investigator_affiliation>
    <investigator_full_name>Peter Bader</investigator_full_name>
    <investigator_title>Prof. Dr. med. Peter Bader</investigator_title>
  </responsible_party>
  <keyword>Allogeneic stem cell transplantation in pediatric patients</keyword>
  <keyword>CD3/CD19 depleted stem cells</keyword>
  <keyword>malignant and non-malignant high risk diseases</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

